Exploring CAR T-cell Therapy

Published on in CHOP News

Stephan A. Grupp, MD, PhD, Director of the Cancer Immunotherapy Frontier Program and Director of Translational Research for the Center for Childhood Cancer Research at Children’s Hospital of Philadelphia (CHOP), explains why CAR T-cell therapy is such a critical tool for treating relapsed pediatric leukemia, how this revolutionary approach of re-engineering immune cells and then infusing them back into a patient’s body to become targeted “cancer killers” works, and how there’s nothing else out there like it … as the therapy continues on its road to approval from the U.S. Food and Drug Administration.

Read the article on ASH Clinical News website.